Den hyppigst rapporterede bivirkning i bryst/ ovariecancer kliniske undersøgelser (50 mg/ m2 hver 4. uge) var palmar- plantar erythrodysesthesi (PPE).
The most common undesirable effect reported in breast/ ovarian clinical trials (50 mg/ m2 every 4 weeks) was palmar-plantar erythrodysesthesia (PPE).